BioSyent Inc. (CVE:RX - Get Free Report) shares passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$11.05 and traded as high as C$11.30. BioSyent shares last traded at C$11.30, with a volume of 1,158 shares traded.
BioSyent Trading Down 1.8 %
The firm has a market cap of C$127.53 million, a price-to-earnings ratio of 18.10 and a beta of 0.93. The firm's 50-day moving average is C$11.07 and its 200-day moving average is C$11.15. The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90.
BioSyent Company Profile
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Featured Stories
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
